Osteoarthritis (OA) including joint inflammation and cartilage degradation is one of the leading causes of lameness in horses, but there is still no cure to prevent the progressive degradation of the joint tissue or restore normal joint anatomy. Therefore, the goals for the treatments used for decades has been to slow the progression of the disease, minimize pain, and increase the function of the joint. The aim of this study was to investigate differences in the in vitro secreted protein profile between naïve and chondrogenic differentiating BM-derived MSCs when exposed to an inflammatory (IL-1) environment.